WellSpring Oncology Patient Education
Source-linked guides about prostate, skin cancer and arthritis radiotherapy, written clearly for patients.
Prostate Radiotherapy
ProtecT found similarly low 15-year prostate cancer mortality after surgery, radiotherapy, or active monitoring, with different risks of progression and long-term side effects.
Arthritis Radiotherapy
Knee arthritis has the strongest recent randomized signal; evidence for other joints is less certain or mostly observational.
Prostate Radiotherapy
A clear guide to metastasis-directed SBRT, the evidence supporting it, and the questions that ongoing trials have not yet answered.
Arthritis Radiotherapy
The evidence is promising for selected patients but not settled, and broad success-rate claims hide important differences among studies.
Prostate Radiotherapy
COMPPARE found no significant difference between proton therapy and IMRT in patient-reported bowel symptoms, grade 2+ GI toxicity, or 3-year freedom from biochemical progression.
Prostate Radiotherapy
ASCENDE-RT found stronger long-term PSA control with a brachytherapy boost, but no significant overall-survival improvement and more urinary toxicity.
Arthritis Radiotherapy
What the new consensus says about evidence, patient selection, dosing, safety, and remaining uncertainty.
Arthritis Radiotherapy
Low-dose radiation is one possible later-line discussion—not a replacement for diagnosis or established osteoarthritis care.
Arthritis Radiotherapy
A practical six-session treatment guide that separates short-term experience from uncertain long-term radiation risk.
Prostate Radiotherapy
Hormone therapy can improve outcomes with prostate radiation, but its duration should reflect cancer risk, health, and side-effect priorities.
Skin Cancer Radiotherapy
Mohs remains preferred for many operable skin cancers; superficial radiation can still be reasonable when surgery is unsuitable or declined.
Arthritis Radiotherapy
Joint-specific evidence matters: randomized hand studies were negative even though newer knee results are encouraging.
Arthritis Radiotherapy
The study improves the evidence for knee osteoarthritis, but it was small and longer follow-up is still needed.
Prostate Radiotherapy
Ten-year FLAME results show better biochemical control from an MRI-guided focal boost, without a demonstrated overall-survival advantage.
Skin Cancer Radiotherapy
C-POST changed the evidence for a narrow high-risk cSCC group; it does not apply to routine superficial lesions.
Prostate Radiotherapy
In PEACE V-STORM, elective pelvic-node radiation plus six months of hormone therapy improved four-year disease control over treating only visible recurrent nodes.
Skin Cancer Radiotherapy
Radiation is an established option for selected basal and squamous skin cancers, but candidacy depends on pathology, depth, location, surgery options, and prior treatment.
Prostate Radiotherapy
PACE-B provides randomized evidence that five-treatment SBRT can be an effective option for selected people with localized prostate cancer.
Prostate Radiotherapy
PACE-A found different quality-of-life tradeoffs after SBRT and surgery, but its small sample does not identify one best treatment for everyone.
Prostate Radiotherapy
PARTIQoL found no meaningful difference in patient-reported quality of life or five-year progression-free survival between proton therapy and IMRT.
Prostate Radiotherapy
The 2024 AUA/ASTRO/SUO guideline explains where PSMA PET fits when PSA rises after prostate surgery.
